A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity

Anti-Cancer Drug Design

Volumn 14, Issue 5, 1999, Pages 393-402

  Stratowa, Christian ^b   Baum, Anke ^b   Castañon, Maria J ^b   Dahmann, Georg ^a   Himmelsbach, Frank ^a   Himmler, Adolf ^b   Loeber, Gerhard ^b   Metz, Thomas ^b   Schnitzer, Renate ^b   Solca, Flavio ^b   Spevak, Walter ^b   Tontsch, Ulrike ^b   Von Rüden, Thomas ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

Cellular assays; Drug discovery; HER2; Parallel screening; Receptor tyrosine kinases

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR;

ANIMALIA; MURINAE;

EID: 0033510286     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Baserga R. (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research, 55, 249.
2. Carraway K.L., Cantley L.C. (1994) A Neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling. Cell, 78, 5.
3. De Potter C.R., Schelfhout A.-M. (1995) The neu-protein and breast cancer. Virchows Archiv, 426, 107.
4. Dexter T.M., Garland J., Scott D., Scolnick E., Metcalf D. (1980) Growth of factor-dependent hemopoietic precusor cell lines. Journal of Experimental Medicine, 152, 1036.
5. Di Renzo M.F., Olivero M., Ferro S., Prat M., Bongarzone I., Pilotti S., Pierotti M.A., Comoglio P.M. (1992) Overexpression of the c-met/hgf receptor gene in human thyroid carcinomas. Oncogene, 7, 2549.
6. Fry D.W., Kraker A.J., Connors R.C., Elliott W.L., Nelson J.M., Showalter H.D.H., Leopold WR. (1994) Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Design, 9, 331.
7. Fry D.W. (1996) Recent advances in tyrosine kinase inhibitors. Annual Reports in Medicinal Chemistry, 31, 151.
8. Gossen M., Bujard H. (1992) Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proceedings of the National Academy of Sciences, USA, 89, 5547.
9. Jeffers M., Rong S., Vande Woude G.F. (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. Journal of Molecular Medicine, 74, 505.
10. Karasuyama H., Rolink A., Melchers F. (1988) Recombinant interleukin 2 or 5, but not 3 or 4, induces maturation of resting mouse B lymphocytes and propagates proliferation of activated B cell blasts. Journal of Experimental Medicine, 167, 1377.
11. King I.C., Feng M., Catino J.J. (1993) High throughput assay for inhibitors of the epidermal growth factor receptorassociated tyrosine kinase. Life Sciences, 53, 1465.
12. Kolch W., Martiny-Baron G., Kieser A., Marmé D. (1995) Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Research and Treatment, 36, 139.
13. Lee A.V., Yee D. (1995) Insulin-like growth factors and breast cancer. Biomedicine and Pharmacotherapy, 49, 415.
14. Levitzky A., Gazit A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science, 267, 1782.
15. Major J.S. (1995) Challenges of high throughput screening against cell surface receptors. Journal of Receptor and Signal Transduction Research, 15, 595.
16. Markovitz D., Goff S., Bank A. (1988) A safe packaging line for gene transfer: separating viral genes on two different plasmids. Journal of Virology, 62, 1120.
17. McCubrey J.A., Steelman L.S., Mayo M.W., Algate P.A., Dellow R.A., Kaleko M. (1991) Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hemato poietic cells: overexpressior of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism. Blood, 78, 921.
18. Miller A.D., Rosman G.J. (1939) Improved retroviral vectors for gene transfer and expression. Biotechniques, 7, 980.
19. Modjtahedi H., Dean C. (1994) The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. International Journal of Oncology, 4, 277.
20. Modjtahedi H., Hickish T., Nicolson M., Moore J., Styles J., Eccles S., Jackson E., Salter J., Sloane J., Spencer L., Priest K., Smith I., Dean C., Gore M. (1996) Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. British Journal of Cancer, 73, 228.
21. Nishikawa R., Ji X.-D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., Huang H.-J. S. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proceedings of the National Academy of Sciences, USA, 91, 7727.
22. Park M., Dean M., Cooper C.S., Schmidt M., O'Brien S.J., Blair D.G., Vande Woude G.F. (1986) Mechanism of met oncogene activation. Cell, 45, 895.
23. Pegram M.D., Lipton A., Hayes D.F, Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A., Slamon D.J. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Journal of Clinical Oncology, 16, 2659.
24. Prat M., Pennacchietti S., Crepaldi T., Chiara F., Comoglio P.M. (1995) The HGF receptor (Met): transduction of signals for invasive cell growth. Antibody, Immunoconjugates and Radiopharmaceuticals, 8, 341.
25. Rak J., Filmus J., Finkenzeller G., Grugel S., Marmé D., Kerbel R.S. (1995) Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Review, 14, 263.
26. Shweiki D., Itin A., Soffer D., Keshet E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843.
27. Stratowa C., Machat H., Bürger E., Himmler A., Schäfer R., Spevak W., Weyer U., Wiche-Catanon, M., Czernilofsky A.P. (1995a) Functional characterization of the human neurokinin receptors NK1, NK2, and NK3 based on a cellular assay system. Journal of Receptor and Signal Transduction Research, 15, 617.
28. Stratowa C., Himmler A., Czernilofsky A.P. (1995b) Use of a luciferase reporter system for characterizing G-protein-linked receptors. Current Opinion in Biotechnology, 6, 574.
29. 659). EMBO Journal, 9, 181.
30. Tang P.C., Sun L., McMahon G. (1996) Indolinone compounds for the treatment of disease. Patent application WO 96/40116.
31. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochemical and Biophysical Research Communications, 187, 1579.
32. Ullrich A., Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203.
33. Von Rüden T., Wagner E.F. (1988) Expression of functional human EGF receptor on murine bone marrow cells. EMBO Journal, 7, 2749.
34. Von Rüden T., Mouchiroud G., Bourette R. P., Ouazana R., Blanchet J.-P., Wagner E.F. (1991) Expression of human CSF-1 receptor induces CSF-1-dependent proliferation in murine myeloid but not in T-lymphoid cells. Leukemia, 5, 3.
35. Waterfield M.D., Mayes E.L.V., Stroobant P., Bennet P.L.P., Young S., Goodfellow P.N., Banting G.S., Ozanne B. (1982) A monoclonal antibody to the human epidermal growth factor receptor. Journal of Cellular Biochemistry, 20: 149.
36. 2 receptors to phospholipase C activates a luciferase reporter gene. Receptors and Channels, 1, 193.
37. Zhen Z., Giordano S., Longati P., Medico E., Campiglio M., Comoglio P.M. (1994) Structural and functional domains critical for constitutive activation of HGF-receptor (Met). EMBO Journal, 9, 1691.